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Abstract
Introduction: Brain-derived neurotrophic factor (BDNF) has established physiological roles in the development and
function of the vertebrate nervous system. BDNF has also been implicated in several human malignancies,
including breast cancer (BC). However, the precise biological role of BDNF and its utility as a novel biomarker have
yet to be determined. The objective of this study was to determine the mRNA and protein expression of BDNF in
a cohort of women with BC. Expression levels were compared with normal background tissues and evaluated
against established pathological parameters and clinical outcome over a 10 year follow-up period.
Methods: BC tissues (n = 127) and normal tissues (n = 33) underwent RNA extraction and reverse transcription,
BDNF transcript levels were determined using real-time quantitative PCR. BDNF protein expression in mammary
tissues was assessed with standard immuno-histochemical methodology. Expression levels were analyzed against
tumour size, grade, nodal involvement, TNM stage, Nottingham Prognostic Index (NPI) and clinical outcome over a
10 year follow-up period.
Results: Immuno-histochemical staining revealed substantially greater BDNF expression within neoplastic cells,
compared to normal mammary epithelial cells. Significantly higher mRNA transcript levels were found in the BC
specimens compared to background tissues (p = 0.007). The expression of BDNF mRNA was demonstrated to increase
with increasing NPI; NPI-1 vs. NPI-2 (p = 0.009). Increased BDNF transcript levels were found to be significantly
associated with nodal positivity (p = 0.047). Compared to patients who remained disease free, higher BDNF expression
was significantly associated with local recurrence (LR) (p = 0.0014), death from BC (p = 0.018) and poor prognosis
overall (p = 0.013). After a median follow up of 10 years, higher BDNF expression levels were significantly associated
with reduced overall survival (OS) (106 vs. 136 months, p = 0.006). BDNF emerged as an independent prognostic
variable in multivariate analysis for disease free survival (DFS) (p = 0.026) and approached significance for OS (p = 0.055).
Conclusion: BDNF expression was found to be significantly higher in BC specimens compared to normal tissue.
Higher transcript levels were significantly associated with unfavourable pathological parameters including nodal
positivity and increasing NPI; and adverse clinical outcomes including LR, death from BC, poor prognosis, reduced
DFS and OS. BDNF offers utility as a prognostic marker and potential for targeted therapeutic strategies.
Introduction & Background
Brain-derived neurotrophic factor (BDNF) belongs to
the neurotrophin (NT) superfamily of polypeptide
growth factors, which includes nerve growth factor
(NGF) and NTs 3-6 [1,2]. NTs and their receptors have
key physiological roles in the development and function
of the central and peripheral nervous systems in verte-
brates [3-5]. However, they are also widely expressed in
non-neuronal tissues [6]. Expression of the BDNF gene
(BDNF) is regulated by the presence of multiple activity
dependent and tissue-specific promoters [7]. BDNF sig-
nals preferentially via its high affinity tyrosine kinase
receptor, tropomyosin receptor kinase B (TrkB). Ligand-
induced receptor dimerisation results in auto-phosphor-
ylation and initiates multiple signalling cascades, includ-
ing the mitogen-activated protein kinase (MAPK),
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phosphatidyl-inositide 3-kinase (PI3K) and phospholi-
pase C-gamma (PLC- g) pathways, that promote cellular
survival [8-11]. However, BDNF also shares a common
low affinity receptor (p75NTR) with the other NTs,
which is a member of the tumor necrosis factor (TNF)
receptor superfamily, implicated in the modulation of
cell survival, cell cycle regulation and cytoskeletal rear-
rangement [8]. The overall cellular response to BDNF
exposure is therefore likely to reflect an equilibrium
between TrkB and p75NTR activity.
BDNF has been implicated in various human patholo-
gies, including: depression, epilepsy, Alzheimer’s, Parkin-
son’s and Huntington’s disease [7,12]. BDNF has also
been associated with several human cancers, both neu-
ronal and non-neuronal, including: neuroblastoma [13],
myeloma [14], ovarian [15,16], lung [17], prostate [18],
hepato-cellular [19], pancreatic [20][21,22], head and
neck squamous cell carcinomas [23] and pulmonary car-
cinoid tumours [24]. Interestingly, the archetypal neuro-
trophic factor NGF has been demonstrated to stimulate
proliferation, angiogenesis and behave as an anti-apop-
totic factor in human breast cancer (BC) [1,25-27] with
potential for therapeutic targeting [28]. In keeping with
this, BDNF has been associated with cell survival in
human BC cell lines [1]. BDNF has also been demon-
strated to be significantly up regulated in oestrogen
receptor alpha (ER-a) positive BCs [29]. Although
increased NT and cognate receptor expression have
been demonstrated in BC [2,30], the precise biological
role of BDNF and its utility as a novel biomarker have
yet to be determined. The objective of this study was to
determine the mRNA and protein expression of BDNF
in a cohort of women with BC. Expression levels were
compared with normal background tissues and evalu-
ated against established pathological parameters and
clinical outcome over a 10 year follow-up period.
Methods
Patients
BC tissues (n = 127) and normal background tissues (n
= 31) were collected from University Hospital of Wales
and St George’s Hospital and Medical School; institu-
tional guidelines, including ethical approval and
informed consent, were followed. Specimens were
obtained immediately after excision during surgery and
stored at -80°C until use. A consultant pathologist
examined haematoxylin and eosin stained frozen sec-
tions to verify the presence of tumour cells in the col-
lected samples. Normal tissue was derived from the
background breast parenchyma of BC patients within
the study group. Medical notes and histology reports
were used to extract the clinico-pathological data
(Table 1). A customized database was established to
record the data.
Tissue Processing, RNA Extraction, cDNA Synthesis & RT-
PCR
Frozen sections of tissue were cut at a thickness of 5-10
mm and kept for routine histological analysis. Addi-
tional 15-20 sections were mixed and homogenized
using a hand-held homogenizer in ice-cold RNA extrac-
tion solution. RNA from cells was extracted using an
RNA extraction kit (AbGene Ltd, Surrey, England, UK).
RNA concentration was quantified using a UV spectro-
photometer (Wolf Laboratories, York, England, UK).
Reverse transcription was carried out using a reverse
transcription kit, cDNA was synthesised using first
strand synthesis with an anchored oligodt primer
(AbGene, Surrey, UK). The polymerase chain reaction
(PCR) was performed using sets of primers (Table 2)
with the following conditions: 5 min at 95°C, 20 seconds
at 94°C, 25 seconds at 56°C, 50 seconds at 72°C for 36
cycles and finally 72°C for 7 minutes. ß-actin was ampli-
fied and used as a house keeping control to verify the
quality of cDNA. PCR products were separated on a
0.8% agarose gel, visualised under UV light, photo-
graphed using a Unisave™ camera (Wolf Laboratories,
Table 1 Clinical and pathological data
Parameter Category Number
Node Status Node positive 54
Node negative 73
Tumour Grade 1 24
2 43
3 58
Tumour Type Ductal 98
Lobular 14
Medullary 2
Tubular 2
Mucinous 4
Non specific 7
TNM staging 1 70
2 40
3 7
4 4
NPI NPI1 68
NPI2 38
NPI3 16
Clinical Outcome Disease free 90
Alive with metastasis 7
With local recurrence 5
Died from breast cancer 16
Died of unrelated disease 9
ER status ER a negative 75
ER a positive 38
ER ß negative 91
ER ß positive 24
Note: missing values reflect discarded/un-interpretable values
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York, England, UK) and recorded with Photoshop
software.
Quantitative Analysis of BDNF
BDNF transcript levels within the above-prepared cDNA
were determined using real-time quantitative PCR,
based on the Amplifluor™ technology, modified from
previous reports [31,32]. Pairs of PCR primers were
designed using the Beacon Designer™ software (Version
2, Palo Alto, California, USA) and synthesized by Sigma-
Aldrich, added to the reverse primer was an additional
sequence, known as the Z sequence (5’-ACTGAACCT-
GACCGTACA-’3) which is complementary to the uni-
versal Z probe (Intergen Inc., Oxford, England, UK).
The product expands one intron (Table 2). Taqman
detection kit for ß-actin was purchased from Perkin-
Elmer. The reaction was carried out using the following:
custom made hot-start Q-master mix Abgene (Surrey,
England, UK), 10 pmol of specific forward primer, 1
pmol reverse primer with the Z sequence (Table 2), 10
pmol of FAM- (fluorogenic reporter dye, carboxyfluores-
cein) tagged probe (Intergen Inc.), and cDNA generated
from 50 ng RNA. The reaction was carried out using
IcyclerIQ™ (Bio-Rad, Hemel Hempstead, England, UK)
which is equipped with an optical unit that allows real-
time detection of 96 reactions, under the following con-
ditions: 94°C for 12 minutes, 50 cycles of 94°C for 15
seconds, 55°C for 40 seconds and 72°C for 20 seconds.
The transcript levels were generated from an internal
standard that was simultaneously amplified with the
samples. The levels of gene expression were then nor-
malized against the housekeeping control CK-19, which
was also quantified in these specimens, to correct for
varying amounts of epithelial tissue between samples
[33]. With every PCR run, a negative control without a
template and a known cDNA reference sample as a
positive control, were included.
Immuno-histochemical Analysis of BDNF in Tissues
Frozen sections of breast tissues (normal and tumour)
were cut at a thickness of 6µm using a cryostat. Sections
were mounted on super frost plus microscope slides, air
dried and then fixed in a mixture of 50% Acetone and
50% methanol. Sections were then placed in Optimax
wash buffer (Biogenex) for 5-10 minutes to rehydrate.
Sections were incubated for 20 minutes in a 10% horse
serum blocking solution and then probed with the pri-
mary antibody, anti-human BDNF (H-117, SC-20981,
Santa Cruz Biotechnologies, Inc.), dilution 1:150 in
Optimax buffer (Biogenex). Sections were rinsed thor-
oughly with wash buffer, before incubation for 30 min-
utes in the secondary biotinylated antibody (Multi-link
Swine anti-goat/mouse/rabbit immunoglobulin, Dako
Inc.). Following thorough washings, sections were incu-
bated for 30 minutes with Avidin Biotin Complex (Vec-
tor Laboratories) followed by further washings. Di-
amino-benzidine (DAB) chromogen (Vector Labs) was
then added to the sections which were incubated in the
dark for 5 minutes. Sections were then washed for 10
minutes in running tap water, prior to nuclear counter
staining with Gill’s Haematoxylin for 1 minute, followed
by a further 10 minute wash with tap water. Sections
were dehydrated in ascending grades of methanol before
clearing in xylene and mounting under a cover slip
using clear mounting medium.
Statistical Analysis
The two-sample t-test (comparison of mean copy num-
ber) was used for statistical analysis of absolute and nor-
malised gene copy number. For normality the
Anderson-Darling test was used. The transcript levels
within the BC specimens were compared to normal
background tissues and analyzed against conventional
pathological parameters and clinical outcome over a 10
year follow-up period. In each case the true copy num-
ber was used for statistical analysis and hence the sam-
ples were not classified as positive or negative. The
statistical analysis was carried out using Minitab version
14.1 (Minitab Ltd. Coventry, England, U.K.) using a cus-
tom written macro (Stat 2005.mtw). For purposes of the
Kaplan-Meier survival analysis, the samples were divided
arbitrarily into two groups, ‘high transcript level’ or ‘low
transcript level’. The cut-off was guided by the Notting-
ham Prognostic Index (NPI) value with which the value
of the moderate prognostic group was used as the divid-
ing line at the start of the test. NPI = tumour size (cm)
× 0.2 + lymph node stage (1 - no nodes affected; 2 - up
to 3 nodes affected; 3 - more than 3 nodes affected) +
Grade (1-3, Scarff-Bloom-Richardson). NPI scores were
classified into three groups: <3.4 = NPI-1, 3.4-5.4 =
NPI-2, >5.4 = NPI-3. Survival analysis was performed
using SPSS version 16.0 (SPSS Inc. Chicago, IL, USA).
Results
BDNF was found to be expressed in both normal breast
tissue and BC specimens. Immunohistochemical staining
for BDNF was substantially more positive within the
neoplastic cells of breast tissues than in normal mam-
mary epithelial cells (Figure 1). BDNF mRNA transcript
Table 2 Forward and reverse primers
BDNF F ACATCATTGGCTGACACTTT
BDNF Zr ACTGAACCTGACCGTACATGCGTCCTTATTGTTTTCTT
CK-19 F CAGGTCCTAGAGGTTACTGAC
CK-19 Zr ACTGAACCTGACCGTACACACTTTCTGCCAGTGTGTCTTC
b-actin F ATGATATCGCCGCGCTCGTC
b-actin Zr CGCTCGGTGAGGATCTTCA
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levels were determined both in absolute terms and nor-
malised against CK-19 in order to correct for varying
amounts of epithelial tissue between samples. Signifi-
cantly higher mRNA transcript levels were found in the
BC specimens compared to the background tissue (abso-
lute mean copy number 13104 vs. 1262, p = 0.007) (Fig-
ure 2). The expression of BDNF mRNA was
demonstrated to increase with increasing NPI; NPI-1 vs.
NPI-2 (normalised mean copy number 2339 vs. 13690, p
= 0.009) and approached significance for NPI-1 vs. NPI-
3 (absolute mean copy number 4586 vs. 8442, p =
0.065) (Figure 3). Increased BDNF transcript levels were
found to be significantly associated with nodal positivity
(normalised mean copy number 2339 vs. 12378, p =
0.047) (Figure 4). Although both absolute and
normalised BDNF transcript levels were found to
increase with tumour grade, this did not reach statistical
significance (Figure 5). Compared to patients who
remained disease free, higher BDNF expression was sig-
nificantly associated with local recurrence (LR) (absolute
mean copy number 6660 vs. 7430, p = 0.0014), death
from BC (absolute mean copy number 6660 vs. 49945, p
= 0.018) and approached significance for those develop-
ing metastases (absolute mean copy number 6660 vs.
33787, p = 0.078) (Figure 6). Overall, significantly higher
transcript levels were found in patients with poor prog-
nosis (LR, metastases or death from BC) compared to
those who remained disease free (absolute mean copy
number 6660 vs. 37243, p = 0.013) (Figure 7). The
expression of BDNF was not found to increase signifi-
cantly with increasing TNM stage.
                                       Normal                                                Tumour 
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x100 
x200 
x400 
Figure 1 Immuno-histochemical analysis of BDNF expression
and localization in BC and normal mammary tissues.
Figure 2 Summary of BDNF expression profiles for normal and
tumour specimens. Values represent the true copy number of
mRNA transcripts, absolute and normalised against CK-19 (inset),
expressed as mean and standard deviation.
Figure 3 Summary of BDNF expression profiles and NPI. Values
represent the true copy number of mRNA transcripts, absolute and
normalised against CK-19 (inset), expressed as mean and standard
deviation.
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Figure 4 Summary of BDNF expression profiles and nodal
status. Values represent the true copy number of mRNA transcripts,
absolute and normalised against CK-19 (inset), expressed as mean
and standard deviation.
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After a median follow up of 10 years, higher BDNF
expression levels, both absolute and normalised, were
significantly associated with reduced overall survival
(OS) times: higher absolute expression levels, mean sur-
vival = 125.36 (95% CI = 107.49-143.24) vs. 134.31 (95%
CI = 123.52-145.11) months, p = 0.041; higher normal-
ised expression levels, mean survival = 105.55 (95% CI =
78.88-132.21) vs. 135.97 (95% CI = 125.07-146.87)
months, p = 0.006 (Figure 8A). The disease free survival
(DFS) curves for women with tumours which were clas-
sified as having ‘high levels’ of BDNF transcript was not
found to differ significantly from that of their ‘low level’
counterparts. The survival curves show higher levels of
BDNF were of marginal benefit in predicting lower DFS:
higher normalised expression levels, mean survival =
102.13 (95% CI = 74.76-129.49) vs. 130.67 (95% CI =
118.79-142.56) months, p = 0.137, NS (Figure 8B). The
independent prognostic utility of BDNF in multivariate
analysis was statistically significant for DFS (p = 0.026)
and narrowly fell short of significance for OS (p =
0.055) (Table 3).
Discussion
NTs and their receptors are increasingly being impli-
cated as novel mediators of carcinogenesis in neuronal
and non-neuronal tissues. Whilst the literature regarding
BC remains sparse, altered expression and function of
these factors are likely to contribute to tumourigenesis
and progression. The present study adds to the litera-
ture in support of the oncogenic function of BDNF in
BC. Furthermore, this study is the first to quantitatively
evaluate BDNF mRNA expression in a large cohort of
BC patients and provide correlation with conventional
pathological parameters and clinical outcomes over an
extended follow-up period. Significantly higher mRNA
transcript levels were found in BC specimens compared
to normal tissue, corroborated at the protein level by
immuno-histochemical staining. BDNF expression was
found to increase with increasing NPI, nodal positivity,
LR, death from BC and poor prognosis overall. After a
median follow up of 10 years, higher BDNF expression
levels were significantly associated with reduced OS.
Furthermore, BDNF remained an independent prognos-
tic variable in multivariate analysis. Our results differ
from those of Blasco-Gutierrez et al. [2] who did not
identify differential staining between tumour and normal
breast tissue and reported no association between BDNF
expression and pathological parameters or clinical out-
comes. In their study, Tozlu et al. [29] employed real-
time quantitative reverse transcription (RT)-PCR to
compare the mRNA expression of 560 selected genes in
BCs excised from 48 women. BDNF emerged as a
growth factor significantly up regulated amongst ER-a
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Figure 5 Summary of BDNF expression profiles and tumour
grade. Values represent the true copy number of mRNA transcripts,
absolute and normalised against CK-19 (inset), expressed as mean
and standard deviation.
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Figure 6 Summary of BDNF expression profiles and clinical
outcomes. Values represent the true copy number of mRNA
transcripts, absolute and normalised against CK-19 (inset), expressed
as mean and standard deviation.
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Figure 7 Summary of BDNF expression profiles and poor
prognosis (LR, metastases or death from BC). Values represent
the true copy number of mRNA transcripts, absolute and normalised
against CK-19 (inset), expressed as mean and standard deviation.
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positive tumours in both the screening and validation
sets. However, the relationship was found to be reversed
in vitro, where BDNF was found to be up regulated in
ER-a negative BC cell lines. Interestingly cross-talk
between steroid and growth factor pathways has been
identified in the brain, with oestrogen implicated in the
regulation of BDNF and demonstrating some degree of
overlap in activity with NTs [34]. BDNF has also been
associated with increased cell survival, although not
proliferation, in human BC cell lines. In accordance
with the fact that BDNF did not demonstrate a mito-
genic effect, no expression of TrkB was found in any of
the BC cells tested. However, the interaction between
BDNF and P75NTR, which specifically induces NF-ϰB,
has been implicated in the protection of BC cells from
apoptosis [1]. Further support for the oncogenic func-
tion of BDNF in vivo comes from a transgenic mouse
model of spontaneous mammary tumor formation, fol-
lowing exposure to the organochlorine pesticide Diel-
drin, which is a persistent environmental toxin thought
to increase the risk of BC [35]. Offspring of these mice
show enhanced development of mammary tumours with
increased mRNA and protein expression of BDNF and
TrkB [36].
The factors regulating NT and NT receptor expression
in normal and malignant breast tissues remain
unknown. Whilst the precise biological role of the
BDNF/TrkB/P75NTR axis in human BC has yet to be
elucidated, supporting evidence of oncogenic function
may be inferred from other malignancies. TrkB has been
implicated in the pathogenesis of neuroblastoma where
expression is correlated with poor outcome and a
chemo-resistant phenotype [37,38], increased mortality
in Wilm’s tumor [39], lymph node metastasis and
advanced stage in non-small cell lung cancer [40],
shorter survival in ovarian cancer [16][15] and distant
metastases and poor prognosis in gastric cancer [41].
TrkB has also been found to regulate migration, inva-
sion and epithelial-mesenchymal transition in head and
neck squamous cell carcinoma [23]. Signalling via the
BDNF/TrkB pathway stimulates pro-survival signals,
resistance to anoikis and altered cellular aggregation, all
features of cancer cells and prerequisites of metastases
formation [42]. Emerging roles for NTs in angiogenesis
provide further insight into their potential relevance to
cancer development and progression [43]. Studies have
identified BDNF and TrkB as key mediators of vascular
development [44]. BDNF is an endothelial survival fac-
tor, deficiency of which results in reduced endothelial
cell-cell contacts and apoptosis [45]. BDNF has been
implicated as a novel angiogenic protein in multiple
myeloma [14,46]. In support of this, BDNF activation of
TrkB has been found to induce vascular endothelial
growth factor (VEGF) expression via hypoxia inducible
factor-1-alpha (HIF-1-a) in neuroblastoma cells [47]. It
has also been suggested that increased expression of
TrkB/BDNF may indicate increased neo-neurogenesis,
where tumors initiate their own innervation by releasing
neurotrophic factors [48]. This may further support
tumour progression by the release of neurotransmitters
which enhance metastasis. Indeed, the presence of nerve
cell markers in tumoral tissue has been found to be a
prognostic marker in several human malignancies [49].
Table 3 Multivariate analysis of prognostic parameters
Parameter Overall Survival (p
value)
Disease Free Survival (p
value)
BDNF
status
0.055 0.026
NPI 0.093 0.035
ER status 0.57 0.042
Grade 0.85 0.079
Stage 0.12 0.308
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Figure 8 BDNF expression levels and Kaplan-Meier analysis for
OS (A) and DFS (B), absolute and normalised against CK-19
(inset).
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In addition to utility as a prognostic marker, therapeutic
manipulation of the TrkB signal transduction pathway
appears to be an increasingly important target in cancer
biology which merits further exploration [11,50]. Despite
the inferences drawn, the mechanisms through which
BDNF exerts its oncogenic activity have yet to be ade-
quately determined and this will undoubtedly be neces-
sary to optimise any potential therapeutic applications.
Limitations of the present study include the use of
background parenchyma from BC patients to provide
‘normal tissue’ for comparison is also contentious. Ide-
ally, such material should be derived from patients with-
out BC in order to avoid any ‘field change’ which may
exist within cancer bearing tissues. Although the sample
size and follow-up period were substantial, it is possible
that a larger cohort, particularly with regard to subgroup
analysis, may have influenced several results which
approached, but failed to reach, statistical significance.
In addition to the measurement of mRNA transcript
levels and qualitative immuno-histochemistry, quantita-
tive analysis of protein expression should be undertaken
to ensure concordance. Correlation with associated
molecules, in particular TrkB and P75NTR, and other
markers of invasiveness and metastatic competence
would also be of value.
Conclusions
BDNF expression was found to be significantly higher in
BC specimens compared to normal tissues. Higher tran-
script levels were significantly associated with unfavour-
able pathological parameters including nodal positivity
and increasing NPI; and adverse clinical outcomes
including LR, death from BC, poor prognosis, reduced
DFS and OS. In addition to the prognostic utility of
BDNF, further mechanistic studies are warranted to
explore the potential for therapeutic manipulation in
human BC.
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